myelin-basic-protein and Intestinal-Neoplasms

Leucocytes from 4 cancer patients showed cellular reactivity in the leucocyte adherence inhibition (LAI) assay in the presence of the synthetic encephalitogenic peptide of human myelin basic protein. All patients exhibited reactivity at a peptide concentration of 500 ng/ml. Leucocytes from 4 non-cancer patients failed to react. Suppression of LAI was detected in all 4 cancer patients by adding their serum to reactive mixtures containing peptide and autologous leucocytes. Each serum was subjected to column chromatography on Sephacryl S-200 to determine the molecular weight distribution of suppressive (blocking) factors. The greatest suppression was found in all cases within the range 90-155 kdalton.

Topics: Aged; Antigens, Neoplasm; Female; Humans; Immunity, Cellular; Immunologic Techniques; Intestinal Neoplasms; Leukocyte Adherence Inhibition Test; Lung Neoplasms; Lymphocytes; Middle Aged; Myelin Basic Protein; Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms

The specific lymphocyte sensitization of patients with malignant diseases against a basic protein, isolated from human brain, was studied by the lymphocyte migration inhibition technique. A sensitization of lymphocytes of cancer patients against this encephalitogenic factor (EF) was first reported by FIELD and CASPARY in 1970. Their test system was the Macrophage-Electrophoretic-Mobility-Test (MEMT). In 17 out of 18 patients with malignant disease we found a specific inhibition or enhancement of the migration area of lymphocytes more than 15%.

Topics: Carcinoma, Bronchogenic; Cell Migration Inhibition; Humans; Intestinal Neoplasms; Lung Neoplasms; Lymphocyte Activation; Lymphoma; Macrophages; Male; Melanoma; Myelin Basic Protein; Neoplasms; Stomach Neoplasms